Karyopharm Therapeutics: Is a Star Born?

Karyopharm Therapeutics Third Quarter Financial Results Generated Revenues
For the first time since its establishment Karyopharm Therapeutics (KPTI) financial results report revenues from a strong launch of its first approved product. Indeed, the firm’s third-quarter 2019 financial results are the first quarter in which Karyopharm generated revenues. In early July the U.S. FDA granted the company’s product Xpovio® (selinexor . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.